[an error occurred while processing this directive] | [an error occurred while processing this directive]
Study of the mechanism of anti-tumor effect of Metformin-enhanced radiotherapy in CT26WT cell lines or mouse models with transplanted tumors
Dai Xichao1, Tao Leilei1, Fang Tingting2, Chen Ping1, Sun Haijun2, Wu Zhifeng2, Dai Xichun3
1Department of Oncology,Yancheng First People′s Hospital,Yancheng 224000,China; 2Intensive Care Unit ,Suqian First Hospital,Suqian 223800,China; 3Department of Oncology, Hongze County people′s Hospital, Huai′an 223001, China
AbstractObjective To investigate the inhibitory effect and mechanism of Metformin (Met) combined with irradiation in CT26WT cell lines or mouse models with transplanted tumors. Methods CT26WT cell line was treated with 0.5μmol/L,1.0μmol/L,5.0μmol/L and 10.0μmol/L Met,and CellTiter Glo kit was used to detect the inhibitory effect of Met at different concentrations on the viability of CT26WT cells. CT26WT cell line was treated with the control,Met (10μmol/L),15Gy irradiation and 15Gy irradiation+Met (10μmol/L). Clone formation assay was employed to detect the cell proliferation activity. Bablc mouse models of transplanted tumors (tumor size>150 mm3) were established and randomly divided into the control, 15Gy irradiation, Met and 15Gy irradiation+Met groups. Mice were given with 750 mg/kg Met at 24 h before irradiation. Transplanted tumor volume was measured regularly to delineate the growth curve of transplanted tumors and survival curve. The expression levels of P-H2AX and Sting proteins in CT26WT cells and transplanted tumors were detected by Western blot. The infiltration of CD8a (+) T cells in transplanted tumor tissues was detected by immunohistochemistry. Results The relative cell survival rate was 100%,87.9%,87.8%,87.3% and 76.5% in the 0, 0.5,1.0,5.0 and 10.0μmol/L Met groups,respectively (all P<0.05). The inhibitory effect of 10.0μmol/L was significantly stronger than that of 5.0μmol/L (P<0.001). The colone formation rate 34.0%,24.0%,22.3% and 14.0% in the control,Met,15Gy irradiation,Met+15Gy irradiation groups, respectively (all P<0.001). Western blot showed that compared with the control group,the expression of Sting protein was increased by 2.99-fold after Met treatment (P<0.001),and increased by 1.37-fold and 4.41-fold in the 15Gy irradiation and 15Gy irradiation+Met groups (both P<0.01). Compared with the 15Gy irradiation group,the expression of P-H2AX protein was significantly increased by 1.43 times after treatment with 15Gy+Met (P<0.001). The transplanted tumor growth curve showed that the transplanted tumor growth in the 15Gy+Met group was slower than that in the control group[(1007.0±388.5) mm3vs. (2639.0±242.9) mm3,P<0.05)]. The overall survival time in the 15Gy irradiation+Met group was 48 d, significantly longer than 32 d in the control group (P<0.001). Compared with the control group,the expression of P-H2AX and Sting proteins in the 15Gy+Met group was increased by 8.8-fold and 1.6-fold (both P<0.001). Immunohistochemical staining showed that the infiltration of CD8a (+) T cells in the 15Gy irradiation+Met group was significantly higher than that in the control group (P<0.01). Conclusions Met combined with radiotherapy can inhibit the proliferation and clone formation of colon cancer cells, probably by aggravating DNA damage and activating the Sting signaling pathway, eventually leading to the increase of CD8a (+) T cells in tumor tissues and enhancing the killing effect upon transplanted tumor cells.
Dai Xichao,Tao Leilei,Fang Tingting et al. Study of the mechanism of anti-tumor effect of Metformin-enhanced radiotherapy in CT26WT cell lines or mouse models with transplanted tumors[J]. Chinese Journal of Radiation Oncology, 2020, 29(3): 203-206.
Dai Xichao,Tao Leilei,Fang Tingting et al. Study of the mechanism of anti-tumor effect of Metformin-enhanced radiotherapy in CT26WT cell lines or mouse models with transplanted tumors[J]. Chinese Journal of Radiation Oncology, 2020, 29(3): 203-206.
[1] Deng L,Liang H,Xu M,et al. STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor imunity in immunogenic tumors[J]. Immunity,2014,41(5):843-852. DOI:10.1016/j.immuni.2014.10.019.
[2] Kiang JG,Garrison BR,Smith JT,et al. Ciprofloxacin as a potential radio-sensitizer to tumor cells and a radio-protectant for normal cells:differential effects on γ-H2AX formation,p53 phosphorylation,Bcl-2 production,and cell death[J]. Mol Cell Biochemist,2014,393(1-2):133-143. DOI:10.1007/s11010-014-2053-z.
[3] Tanaka Y,Chen ZJ. STING specifies IRF3 phosphorylation by TBK1 in the cytosolic DNA signaling pathway[J]. Sci Signal,2012,5(214):ra20. DOI:10.1126/scisignal.2002521.
[4] Li XD,Wu J,Gao D,et al. Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects[J]. Science,2013,341(6152):1390-1394. DOI:10.1126/science.1244040.
[5] Huber JP,Farrar JD. Regulation of effector and memory T-cell functions by type I interferon[J]. Immunology,2011,132(4):466-474. DOI:10.1111/j.1365-2567.2011.03412.x.
[6] Sanli T,Rashid A,Liu C,et al. Ionizing radiation activates AMP-activated kinase (AMPK):a target for radiosensitization of human cancer cells[J]. Int J Radiat Oncol Biol Phys,2010,78(1):221-229. DOI:10.1016/j.ijrobp.2010.03.005.
[7] Skinner HD,Sandulache VC,Ow TJ,et al.tp53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence[J]. Clin Cancer Res,2012,18(1):290. DOI:10.1158/1078-0432.ccr-11-2260.
[8] Zhang Y,Storr SJ,Kerstie J,et al. Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy[J]. Oncotarget,2014,5(24):12936-12949. DOI:10.18632/oncotarget.2683.
[9] Kim EH,Kim MS,Cho CK,et al. Low and high linear energy transfer radiation sensitization of HCC cells by metformin[J]. J Radiat Res,2013,55(3):432-442. DOI:10.1093/jrr/rrt131.
[10] Group UPDS. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)[J]. Lancet,1998,352(9131):854. DOI:10.1016/s0140-6736(98)07037-8.
[11] Noto H,Goto A,Tsujimoto T,et al. Cancer risk in diabetic patients treated with metformin:a systematic review and meta-analysis[J/OL]. Plos One,2012,7(3):e33411. DOI:10.1371/journal.pone.0033411.
2020, Vol. 29 
